BI Asset Management Fondsmaeglerselskab A S Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

BI Asset Management Fondsmaeglerselskab A S lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 61.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,697 shares of the biopharmaceutical company’s stock after selling 9,172 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Alnylam Pharmaceuticals were worth $1,885,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ALNY. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $243,000. Geneos Wealth Management Inc. raised its holdings in Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 175 shares during the last quarter. Flow Traders U.S. LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $241,000. Daiwa Securities Group Inc. lifted its position in Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 70,300.0% during the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 703 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $288.18 on Wednesday. The firm has a market cap of $38.47 billion, a PE ratio of 78.74 and a beta of 0.29. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The firm has a fifty day simple moving average of $298.80 and a two-hundred day simple moving average of $334.73. Alnylam Pharmaceuticals, Inc. has a 1-year low of $273.11 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s revenue was up 96.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.44) EPS. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current year.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, June 4th. Jefferies Financial Group reaffirmed a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Wells Fargo & Company lifted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Truist Financial decreased their target price on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $463.13.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 7,740 shares of company stock valued at $2,420,214. 0.86% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.